AzTrials
AzTrials

AsthmaMI-ACTNCT01381159

Motivational Intervention for Asthma

A study testing Motivational Communication in people with Asthma, run by Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal at 1 site in Canada.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The high burden of asthma appears to be related to poor asthma control, which is associated with more frequent asthma symptoms, greater bronchodilator use and functional impairment, and worse pulmonary function. Despite the availability of effective treatments, more than 58% of asthmatics are poorly controlled. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Asthma
What is being tested?
Motivational Communication
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
58 participants
Where
1 siteCanada
Study dates
Jan 2011to Aug 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients 18 years and older
  • Primary diagnosis of moderate-severe persistent asthma (as per GINA)
  • Prescribed inhaled corticosteroid medication (min dose of 250 µg fluticasone equivalent per day) for at least 12 consecutive months
  • Uncontrolled asthma (≥ 1.25 on the Asthma Control Questionnaire)
  • Covered by a drug insurance plan (e.g., RAMQ)
  • Non-adherent to ICS medication (based on having filled less than 50% of their prescriptions over the last year)
  • Able to speak English or French.

Who cannot join

  • Any other medical condition that confers greater illness morbidity than asthma (e.g., active cancer)
  • Severe psychopathology (e.g., schizophrenia)
  • Apparent cognitive or language deficit
  • Are or plan to become pregnant or move outside of Quebec over the course of the study.

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • Hopital du Sacre-Coeur de Montreal

    Montreal, Quebec, H4J 1C5

Other trials in Canada

About this study

Official title: Motivational Intervention for Asthma Control Trial

The high burden of asthma appears to be related to poor asthma control, which is associated with more frequent asthma symptoms, greater bronchodilator use and functional impairment, and worse pulmonary function. Despite the availability of effective treatments, more than 58% of asthmatics are poorly controlled. Daily adherence to inhaled corticosteroid (ICS) regimens is considered by experts to be one of the most important behavioural factors linked to achieving optimal asthma control. However, there is a paucity of research on interventions specifically designed to improve ICS adherence among adult asthmatics. The vast majority of intervention studies to date used atheoretical interventions to target behaviour change, relying mainly upon educational approaches which have been criticised for "failing to translate knowledge into action." This may be due to the fact that most education-based approaches do not specifically address or help patients overcome ambivalence about behaviour change, which is necessary for ensuring daily adherence. Motivational communication (MC) is a client-centred intervention that focuses on enhancing intrinsic motivation to change a particular behaviour, and exploring and resolving ambivalence about behaviour change. Brief MC sessions (e.g., 1-5 x 15-30 minute sessions) have been shown to improve a variety of health behaviours (e.g., reduce alcohol consumption, improve dietary habits, increase exercise behaviour, and improve medication adherence) and health outcomes (reduce blood pressure, body mass index, and cholesterol levels). However, no studies to date have assessed the efficacy of using MC to improve ICS adherence in asthmatics. This study aims to assess the efficacy of using MC to improve daily medication (ICS) adherence in a sample of poorly controlled, non-adherent asthmatics. It is hypothesized that patients randomized to the MC condition will exhibit significantly improved ICS adherence at 6 and 12-months post-intervention, independent of baseline levels and covariates, relative to patients randomized to the usual care control condition.

Read the detailed description

Background: The high burden of asthma, which affects 300 million people worldwide, appears to be related to poor asthma control, which is associated with more frequent asthma symptoms, greater bronchodilator use and functional impairment, and worse pulmonary function. The availability of effective treatments suggests that asthma can be well controlled in most patients. However, Canadian statistics reveal that over 58% of asthmatics are poorly controlled. Achieving optimal asthma control relies upon several behavioral factors, including minimizing exposure to known triggers (e.g., pets, dust, pollen) and improving health behaviors (e.g,. quitting smoking and adhering to medication). Of these, daily adherence to inhaled corticosteroid (ICS) regimens is considered by experts to be one of the most important behavioral factors linked to achieving optimal asthma control. This is because taking ICS medications as prescribed (i.e., good adherence) has been shown to be effective for achieving good asthma control even in patients who fail to adequately manage/minimize exposure to known triggers (e.g., indoor allergens, exercise). Despite the efficacy of ICS's, recent trends in adherence behaviour suggest that asthmatics are not adherent to these medications, with rates being as low as 32%, even in patients with severe asthma. Explanations range from simply forgetting to having distorted/ erroneous illness and medication beliefs. Currently, there is a paucity of research on interventions specifically designed to improve ICS adherence among adult asthmatics. Most previous work has been conducted in pediatric samples which have yielded inconsistent results that are difficult to generalize to adult samples. Of the studies conducted among adults, most suffer from important methodological limitations (e.g., small sample sizes, no intent to treat analyses, failure to control for contact time, no objective measure of adherence) that make it difficult to either generalize findings or interpret them with confidence. Most importantly, the vast majority of intervention studies to date used atheoretical interventions to target behaviour change, relying mainly upon educational approaches which have been criticised for "failing to translate knowledge into action." This may be due to the fact that most education-based approaches do not specifically address or help patients overcome ambivalence about behaviour change, which is necessary for ensuring daily adherence. Motivational communication (MC) is a client-centred intervention that focuses on enhancing intrinsic motivation to change a particular behaviour (i.e., take medication as prescribed), and exploring and resolving ambivalence about behaviour change. Brief MC sessions (e.g., 1-5 x 15-30 minute sessions) have been shown to improve a variety of health behaviours (e.g., reduce alcohol consumption, improve dietary habits, increase exercise behaviour, and improve medication adherence) and health outcomes (reduce blood pressure, body mass index, and cholesterol levels). No studies to date have assessed the efficacy of using MC to improve ICS adherence in asthmatics. Objective: The purpose of this study is to conduct a single site RCT to assess the efficacy of using MC to improve daily medication (ICS) adherence in a sample of poorly controlled, non-adherent asthmatics. A brief (3-5 x 15-30 minute sessions), manualized MC intervention was developed by our laboratory using pilot funding. This intervention is empirically-driven and uses established behavioural and motivational strategies to encourage change. Methods: 182 poorly controlled, non-adherent adult asthmatics will be recruited from the outpatient asthma clinic of Hôpital du Sacré-Coeur de Montreal (HSCM). Patients will be screened on the day of their asthma clinic visit to verify eligibility. Eligible patients consenting to have their medical and pharmacy records verified by the research team and who are identified as both having poorly controlled asthma (Asthma Control Questionnaire score ≥1.25) and being non-adherent to ICS medication (filled < 50% of their ICS medication in the last year) will be invited to participate in the study. Patients will undergo baseline assessments (pulmonary function, asthma control, self-efficacy, and quality of life) and will then be randomly assigned to a usual care + MC or usual care comparison group. This trial has been designed to conform to the CONSORT guidelines. The primary outcome measure will be ICS adherence at 12 months post-intervention, with preliminary analyses conducted at 6-months post-intervention. Adherence will be measured according to the following validated equation: # of treatment days (based on the # of canisters filled at the pharmacy x the duration of each prescription) divided by the # of prescription days (# of days the patient is expected to be taking his/her medication). Data will be obtained by accessing the patient's pharmacy records and drug insurance databases (i.e., RAMQ, reMed). Secondary outcomes include self-reported medication adherence, adherence motivation, stage of change, pulmonary function, asthma control, self-efficacy, and quality of life scores 6 \& 12 months post-intervention. Impact: This will be the first appropriately designed RCT to test the impact of a brief, manualized MC intervention on asthma medication (ICS) adherence that may be easily incorporated into existing education programs and/or clinical practice and may significantly improve asthma outcomes.

Conditions
Asthma
Being tested
Motivational Communication, Control
Keywords
Adherence, Asthma Control, Asthma Quality Of Life, Motivational Communication, Motivational Interviewing
Medical subject headings
Asthma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Motivational CommunicationBehavioural

    Brief MC sessions focused on medication adherence within 4-6 week period

  • ControlBehavioural

    Standard medical care

Study groups in NCT01381159
Study groupRoleWhat they receive
Motivational CommunicationExperimentalUp to 3 x 30 minute brief MC sessions within 4-6 week period
Receives: Behavioral: Motivational Communication
ControlPlacebo comparatorUsual care
Receives: Behavioral: Control

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Inhaled corticosteroid adherence

    Inhaled corticosteroid adherence measured according to the following validated equation: # of treatment days (based on the # of canisters filled at the pharmacy x the duration of each prescription) divided by the # of prescription days (# of days the patient is expected to be taking his/her medication)

    Measured: 12 months post-intervention

Secondary outcomes (5)
  1. Inhaled corticosteroid adherence

    Inhaled corticosteroid adherence measured according to the following validated equation: # of treatment days (based on the # of canisters filled at the pharmacy x the duration of each prescription) divided by the # of prescription days (# of days the patient is expected to be taking his/her medication)

    Measured: 6 months post-intervention

  2. Asthma Control Questionnaire (Juniper)

    Self report measure of asthma symptoms

    Measured: 12 months post-intervention

  3. Asthma Control Test

    Self report measures of asthma symptoms

    Measured: 12 months post-intervention

  4. Asthma Self-Efficacy Scale (Tobin)

    Self report measure of asthma self-efficacy, i.e., perceived ability to deal with asthma

    Measured: 12 months post-intervention

  5. Mini Asthma Quality of Life Questionnaire (Juniper)

    Self report measure of how asthma influences quality of life

    Measured: 12 months post-intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jun 2011 (estimated)
  2. Study startJan 2011
  3. Primary completionAug 2019
  4. Study completionAug 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
58 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01381159
Sponsor's protocol ID
MBMC002
Other IDs
MOP 111123
Acronym
MI-ACT
Status last verified
Mar 2022
First submitted
21 Jun 2011
Last updated
15 Mar 2022
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Motivational Communication in people with Asthma, run by Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 15 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Inhaled corticosteroid adherence (time frame: 12 months post-intervention). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Mar 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in